Literature DB >> 9332302

The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies.

C Preudhomme1, P Fenaux.   

Abstract

Entities:  

Mesh：

Year:  1997        PMID： 9332302     DOI： 10.1046/j.1365-2141.1997.2403057.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  16 in total

1.  Screening of the entire coding region of p53 in low grade lymphoproliferative disorders.

Authors:  T J Bromidge; D J Howe
Journal:  Mol Pathol       Date:  2000-08

2.  Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model.

Authors:  Nina Richartz; Eva Duthil; Anthony Ford; Elin Hallan Naderi; Sampada Bhagwat; Karin M Gilljam; Marta Maria Burman; Ellen Ruud; Heidi Kiil Blomhoff; Seham Skah
Journal:  Blood Adv       Date:  2019-11-12

Review 3.  The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans.

Authors:  Vinod Pant; Alfonso Quintás-Cardama; Guillermina Lozano
Journal:  Blood       Date:  2012-09-27       Impact factor: 22.113

4.  Targeting p53 for Novel Anticancer Therapy.

Authors:  Zhen Wang; Yi Sun
Journal:  Transl Oncol       Date:  2010-02       Impact factor: 4.243

5.  P53 gene mutations in non-Hodgkin's lymphoma.

Authors:  Y Chen; Z Xiang; H Li; N Yang; H Zhang
Journal:  J Tongji Med Univ       Date:  1999

6.  The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.

Authors:  Derville O'Shea; Ciarán O'Riain; Claire Taylor; Rachel Waters; Emanuela Carlotti; Finlay Macdougall; John Gribben; Andreas Rosenwald; German Ott; Lisa M Rimsza; Erlend B Smeland; Nathalie Johnson; Elias Campo; Timothy C Greiner; Wing C Chan; Randy D Gascoyne; George Wright; Louis M Staudt; T Andrew Lister; Jude Fitzgibbon
Journal:  Blood       Date:  2008-07-15       Impact factor: 22.113

7.  Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.

Authors:  Ken H Young; Karen Leroy; Michael B Møller; Gisele W B Colleoni; Margarita Sánchez-Beato; Fábio R Kerbauy; Corinne Haioun; Jens C Eickhoff; Allen H Young; Philippe Gaulard; Miguel A Piris; Terry D Oberley; William M Rehrauer; Brad S Kahl; James S Malter; Elias Campo; Jan Delabie; Randy D Gascoyne; Andreas Rosenwald; Lisa Rimsza; James Huang; Rita M Braziel; Elaine S Jaffe; Wyndham H Wilson; Louis M Staudt; Julie M Vose; Wing C Chan; Dennis D Weisenburger; Timothy C Greiner
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

8.  Mutation of the p53 tumour suppressor gene and overexpression of its protein in 62 Japanese non-Hodgkin's lymphomas.

Authors:  H Kamata; S Mitani; M Fujiwara; N Aoki; S Okada; S Mori
Journal:  Clin Exp Med       Date:  2007-07-04       Impact factor: 3.984

Review 9.  Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature.

Authors:  Karin Kast; Mechthild Krause; Markus Schuler; Katrin Friedrich; Barbara Thamm; Andrea Bier; Wolfgang Distler; Stefan Krüger
Journal:  BMC Cancer       Date:  2012-06-06       Impact factor: 4.430

10.  Intronic SNPs of TP53 gene in chronic myeloid leukemia: Impact on drug response.

Authors:  K Sailaja; V R Rao; Satish Yadav; R Rajasekhar Reddy; D Surekha; D Nageswara Rao; D Raghunadharao; S Vishnupriya
Journal:  J Nat Sci Biol Med       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.